TMDX logo

TransMedics Group, Inc. Stock Price

NasdaqGM:TMDX Community·US$2.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 156 Fair Values set on narratives written by author

TMDX Share Price Performance

US$68.94
68.94 (0.00%)
US$117.89
Fair Value
US$68.94
68.94 (0.00%)
41.5% undervalued intrinsic discount
US$117.89
Fair Value
Price US$68.94
AnalystConsensusTarget US$117.89
AnalystLowTarget US$118.00
AnalystHighTarget US$190.00

TMDX Community Narratives

·
Fair Value US$117.89 41.5% undervalued intrinsic discount

TMDX: Expanding Organ Donor Pool And Clinical Trials Will Shape Future Direction

2users have liked this narrative
0users have commented on this narrative
66users have followed this narrative
·
Fair Value US$118 41.6% undervalued intrinsic discount

Cost Pressures And Supply Risks Will Weaken Transplant Market Viability

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$190 63.7% undervalued intrinsic discount

Transplant Logistics Will Meet Demand From An Aging World

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
US$118
41.6% undervalued intrinsic discount
Revenue
18.45% p.a.
Profit Margin
18.77%
Future PE
27.64x
Price in 2029
US$146.08
US$190
63.7% undervalued intrinsic discount
Revenue
20.32% p.a.
Profit Margin
22.92%
Future PE
34.74x
Price in 2029
US$234.85

Trending Discussion

Updated Narratives

TMDX logo

TMDX: Organ Trial Progress And Clinical Moat Will Shape Future Upside Potential

Fair Value: US$117.89 41.5% undervalued intrinsic discount
66 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TMDX logo

TMDX: Clinical Trials And 2026 Outlook Will Drive The Next Leg

Fair Value: US$118 41.6% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
1 users have liked this narrative
TMDX logo

TMDX: Organ Platform Expansion And Trials Will Support Future Repricing

Fair Value: US$190 63.7% undervalued intrinsic discount
4 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with solid track record.

1 Risk
4 Rewards

TransMedics Group, Inc. Key Details

US$635.9m

Revenue

US$260.2m

Cost of Revenue

US$375.7m

Gross Profit

US$203.8m

Other Expenses

US$171.9m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
4.97
59.09%
27.04%
103.9%
View Full Analysis

About TMDX

Founded
1998
Employees
898
CEO
Waleed Hassanein
WebsiteView website
www.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Recent TMDX News & Updates

Narrative Update May 15

TMDX: Organ Trial Progress And Clinical Moat Will Shape Future Upside Potential

TransMedics Group's updated analyst price target moves from about $144 to around $118, as analysts factor in slightly higher discount rates, modest tweaks to revenue growth assumptions, stronger projected profit margins, and a lower future P/E multiple following a series of revised models and rating changes across the Street. Analyst Commentary Recent research shows a clear shift in tone, with earlier optimism around growth and profitability now balanced by a round of target cuts and at least one downgrade.

Recent updates

No updates